Page 56 - TD-3-4

Tumor Discovery PPAR agonist and cancer

doi: 10.1007/s00011-019-01231-1 membrane. Microvasc Res. 1994;47(1):31-40.
48. Wu L, Guo C, Wu J. Therapeutic potential of PPARγ natural doi: 10.1006/mvre.1994.1003
agonists in liver diseases. J Cell Mol Med. 2020;24(5):2736-2748.
59. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras
doi: 10.1111/jcmm.15028 mutations in non-small-cell lung carcinoma: A review. Clin
49. Park KS, Choi SH, Chung SS. Re-highlighting the action of Lung Cancer. 2006;8(1):30-38.
PPARγ in treating metabolic diseases [version 1; referees: 2 doi: 10.3816/CLC.2006.n.030
approved]. F1000Res. 2018;7:1127.
60. Girnun GD, Chen L, Silvaggi J, et al. Regression of drug-
doi: 10.12688/f1000research.14136.1 resistant lung cancer by the combination of rosiglitazone
50. Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural and carboplatin. Clin Cancer Res. 2008;14(20):6478-6486.
product agonists of peroxisome proliferator-activated doi: 10.1158/1078-0432.CCR-08-1128
receptor gamma (PPARγ): A review. Biochem Pharmacol.
2014;92(1):73-89. 61. Xu YJ, Zheng Z, Cao C, Li J, Liu Y. Bioanalytical insights
into the association between eicosanoids and pathogenesis
doi: 10.1016/j.bcp.2014.07.018 of hepatocellular carcinoma. Cancer Metastasis Rev.
51. Lebovitz HE. Thiazolidinediones: The forgotten diabetes 2018;37:269-277.
medications. Curr Diab Rep. 2019;19(12):151. doi: 10.1007/s10555-018-9747-8
doi: 10.1007/s11892-019-1270-y 62. Panigrahy D, Kaipainen A, Greene ER, Huang S. Cytochrome
52. Krishnappa M, Patil K, Sharma S, et al. Effectiveness of The P450-derived eicosanoids: the neglected pathway in cancer.
PPAR Agonist Saroglitazar in Nonalcoholic Steatohepatitis: Cancer Metastasis Rev. 2010;29:723-735.
Positive Data from Preclinical and Clinical Studies. Preprint doi: 10.1007/s10555-010-9264-x
(Version 1), Research Square; 2020.
63. Wu L, Wang W, Dai M, Li H, Chen C, Wang D. PPAR-α
doi: 10.21203/rs.3.rs-123364/v1 ligand, AVE8134, and cyclooxygenase inhibitor therapy
53. Harrity T, Farrelly D, Tieman A, et al. Muraglitazar, synergistically suppress lung cancer growth and metastasis.
a novel dual (α/γ) peroxisome proliferator–activated BMC Cancer. 2019;19(1):1166.
receptor activator, improves diabetes and other metabolic doi: 10.1186/s12885-019-6379-5
abnormalities and preserves β-cell function in db/db mice.
Diabetes. 2006;55(1):240-248. 64. Mustafa A, Kruger WD. Suppression of tumor formation by
a cyclooxygenase-2 inhibitor and a peroxisome proliferator-
doi: 10.1111/jcmm.15028 activated receptor gamma agonist in an in vivo mouse
54. Fagerberg B, Edwards S, Halmos T, et al. Tesaglitazar, a novel model of spontaneous breast cancer. Clin Cancer Res.
dual peroxisome proliferator-activated receptor α/γ agonist, 2008;14(15):4935-4942.
dose-dependently improves the metabolic abnormalities doi: 10.1158/1078-0432.CCR-08-0958
associated with insulin resistance in a non-diabetic
population. Diabetologia. 2005;48:1716-1725. 65. Malakouti P, Mohammadi M, Boshagh MA, Amini A,
Rezaee MA, Rahmani MR. Combined effects of
doi: 10.1007/s00125-005-1846-8 pioglitazone and doxorubicin on migration and invasion
55. Augimeri G, Giordano C, Gelsomino L, et al. The role of of MDA-MB-231 breast cancer cells. J Egypt Natl Canc Inst.
PPAR-γ ligands in breast cancer: From basic research to 2022;34(1):13.
clinical studies. Cancers (Basel). 2020;12(9):2623. doi: 10.1186/s43046-022-00110-x
doi: 10.3390/cancers12092623 66. Pfeffer CM, Singh ATK. Apoptosis: A target for anticancer
56. Kim TW, Hong DW, Hong SH. CB13, a novel PPARγ ligand, therapy. Int J Mol Sci. 2018;19(2):448.
overcomes radio-resistance via ROS generation and ER doi: 10.3390/ijms19020448
stress in human non-small cell lung cancer. Cell Death Dis.
2020;11(10):848. 67. Elstner E, Müller C, Koshizuka K, et al. Ligands for
peroxisome proliferator-activated receptorgamma and
doi: 10.1038/s41419-020-03065-w retinoic acid receptor inhibit growth and induce apoptosis
57. Youssef J, Badr M. Peroxisome proliferator-activated of human breast cancer cells in vitro and in BNX mice. Proc
receptors and cancer: Challenges and opportunities. Br J Natl Acad Sci U S A. 1998;95(15):8806-8811.
Pharmacol. 2011;164(1):68-82. doi: 10.1073/pnas.95.15.8806
doi: 10.1111/j.1476-5381.2011.01383.x
68. Ramos-Nino ME, Littenberg B. A novel combination:
58. Nguyen M, Shing Y, Folkman J. Quantitation of angiogenesis ranpirnase and rosiglitazone induce a synergistic apoptotic
and antiangiogenesis in the chick embryo chorioallantoic effect by down-regulating Fra-1 and Survivin in cancer cells.

Volume 3 Issue 4 (2024) 13 doi: 10.36922/td.4003